deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03431077

A Study of LJPC-501 in Pediatric Patients With Hypotension

An Open-Label, Multi-Center Study of LJPC-501 in Pediatric Patients Who Remain Hypotensive Despite Receiving Fluid Therapy and Vasopressor Therapy

Sponsor: La Jolla Pharmaceutical Company

Conditions Catecholamine-resistant Hypotension (CRH) Distributive Shock High Output Shock Sepsis
Interventions Angiotensin II
Updated 7 times since 2018 Last updated: Aug 6, 2018 Started: Feb 11, 2018 Primary completion: Apr 14, 2018 Completion: Apr 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Catecholamine-resistant Hypotension (CRH) and Distributive Shock, this trial is completed. The trial is conducted by La Jolla Pharmaceutical Company and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotRecruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotRecruiting~Sep 2018 – ~Sep 2020 · 24 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

  5. Sep 2018 — Sep 2020 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

▶ Show 2 earlier versions

  1. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  2. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • La Jolla Pharmaceutical Company
Data source: La Jolla Pharmaceutical Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations